Astellas Pharma, Inc.’s Izervay (avacincaptad pegol intravitreal solution) is the second drug approved in the US for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in six months, following the US Food and Drug Administration’s approval of Apellis Pharmaceuticals, Inc.’s Syfovre (pegcetacoplan injection) in February, and will test the early commercial traction that Apellis has reached.
Key Takeaways
- Astella’s Pharma’s Izervay is the second drug newly approved for geographic atrophy.
The two drugs are the first approved for geographic atrophy and are competing for share in the potentially multi-billion-dollar market....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?